InvestorsHub Logo
Followers 0
Posts 83
Boards Moderated 0
Alias Born 05/13/2016

Re: None

Friday, 10/27/2017 6:07:39 PM

Friday, October 27, 2017 6:07:39 PM

Post# of 108192
MRK pulls EU application
for Keytruda in combo with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC).

Late Friday, Merck said that it had withdrawn its European application for Keytruda to treat metastatic nonsquamous non-small cell lung cancer, but did not list a specific reason for the withdrawal.

FYI
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News